108 results about "Tumor-associated macrophage" patented technology

Methods for the treatment of cancer with therapies targeting tumor-associated macrophage activities are provided. Methods for the treatment of cancer, inflammatory and autoimmune disorders with therapies using tumor-associated macrophages and adipose tissue macrophages are also provided.

The invention discloses a macrophage drug-loaded MP (microparticle) preparation and a preparation method thereof. The macrophage drug-loaded MP preparation comprises cell vesicles and drug small molecule effective components wrapped in the cell vesicles, wherein the cell vesicles are released by apoptosis of mannose modified macrophages. The drug-loaded microparticles can be highly enriched in tumor tissue and more easily absorbed by M2 type tumor-related macrophages, the antipolarization effect of small molecule drugs on M2 type tumor-related macrophages is improved, the tumor microenvironment is improved, killing of tumor cells is enhanced, the problems that small molecule drugs cannot be effectively enriched or target and antipolarize M2 type tumor-related macrophages at tumor sites canbe solved, and toxic and side effects of the small molecule drugs on organisms are also reduced.

Provided herein are compositions including particles that comprise a bisphosphonate compound and a tumor specific targeting peptide or peptidomimetic. Also provided herein are methods of reducing tumor associated macrophages and methods of treating cancer with said compositions.

The invention discloses double-target polypeptide of a tumor-associated macrophage, a nano particle, preparation and an application and relates to the technical field of bioscience and drug carriers.The double-target polypeptide is prepared by series connection of alpha helix polypeptide, a catenation sequence and M2 macrophage target peptide in a covalent bond form. The nano particle prepared bythe double-target polypeptide can perform efficient targeted transportation of drugs to the tumor-associated macrophage, so that the tumor-associated macrophage is specifically eliminated and tumor growth is inhibited; a preparation technology of the nano particle targeting to the tumor-associated macrophage is simple; large-scale production is facilitated; most raw materials for preparing the nano particle are used clinically or used in clinical experiments; and a detection result shows that no toxic or side effects are caused on physiologic and biochemical indexes of a mouse.

The invention discloses an miRNA-supported composite nanoparticle. The miRNA-supported composite nanoparticle is prepared from a cation targeted membrane material, an acid sensitivity membrane material and at least one miRNA, wherein the cation targeted membrane material is selected from a galactose-polylysine-polycysteine polymer; the acid sensitivity membrane material is selected from a polyethylene glycol-polylysine polymer of which a side chain is modified by 3,4,5,6-tetrahydrophthalic anhydride ligand; and the miRNA is selected from miRNA for inducing differentiation from tumor-associatedmacrophage to M1 type macrophage. According to the miRNA-supported composite nanoparticle disclosed by the invention, accurate delivery of the tumor-associated macrophage is realized by pH value targeting and active targeting, and the function of promoting the differentiation from the tumor-associated macrophage to the M1 type macrophage is realized.

The present invention relates to cancer immunotherapy. In particular, provided herein are fusion proteins for targeting tumor associated macrophages with immunostimulatory agents.

The present invention features methods of directly targeting specific cell surface receptors on the M2 macrophage for antibody or nanoparticle directed therapy.

The invention relates to a traditional Chinese medicine-magnetic nanocluster chemical immunity drug delivery system and a preparation method thereof. The traditional Chinese medicine-magnetic nanocluster chemical immunity drug delivery system comprises superparamagnetic oxide nanoparticles, wherein the surface of each superparamagnetic oxide nanoparticle is anchored with a drug and a TAMs (tumor-associated macrophage) targeting ligand; the superparamagnetic oxide nanoparticles form a nanocluster structure through disulfide bonds; the nanocluster structure is externally packaged with protein. The traditional Chinese medicine-magnetic nanocluster chemical immunity drug delivery system has the advantages that the target finding advantages of magnetic trend, ligand modifying and reductive sensitization are integrated; the in-vivo circulation is stable, the tumor aggregation efficiency is high, and the TAMs targeting is precise.

The invention belongs to the technical field of medicines, and particularly relates to an immune targeting functional liposome as well as a preparation method and application thereof. The functional liposome disclosed by the invention is a blank liposome which does not entrap a drug, a membrane material contains carbohydrate ligand modified PEGylated phospholipid, the average particle size is 50-500nm, and the functional liposome has a targeting function on immunosuppressive cells in a tumor microenvironment and can promote tumor-associated macrophages to differentiate into M1 type macrophages; the polypeptide has a certain capacity of inhibiting tumor growth, can be used as an adjuvant of a tumor immune treatment, and can also be used as an entrapped delivery tool of an immunomodulator oran anti-tumor drug.

The present invention relates to a pharmaceutical composition that is anticancer and suppresses cancer metastasis, containing a fusion peptide as an active ingredient. More specifically, the present invention relates to a pharmaceutical composition exhibiting an excellent anticancer effect and an cancer metastasis suppression effect by simultaneously targeting a cancer cell and a tumor associated macrophage (TAM) in which IL-4 receptors are over-expressed. The pharmaceutical composition of the present invention simultaneously targets a tumor cell and a TAM and kills the cells, thereby simultaneously having an anticancer effect and a cancer metastasis suppression effect. In addition, the fusion peptide of the present invention decreases side effects of conventional anticancer drugs and exhibits anticancer and cancer metastasis suppression effects, when co-administered with conventional anticancer drugs.

The invention relates to a lipid nano-scale ultrasound contrast agent for targeting tumor-associated macrophages as well as a preparation method and application thereof. The lipid nano-scale ultrasound contrast agent for the targeting tumor-associated macrophages disclosed by the invention takes lipids as a shell membrane material, and wraps low-molecular-weight hyaluronic acids and gaseous fluorocarbon in the shell membrane; and the lipids consist of dipalmitoyl-phosphatidylcholine (DPPC), distearoyl-phosphatidylethanolamine (DSPE) and distearyl phosphatidylethanolamine-polyethylene glycol-folic acids (DSPE-PEG-FOL). The lipid nano-scale ultrasound contrast agent has a particle size of 255-497 nm, and is capable of passing through vascular wall space of tumor tissue so as to achieve tumortreatment effects with passive targeting and high efficiency; PEG chain is utilized so as to have coupled folic acids located outside the lipids shell membrane and the low-molecular-weight hyaluronicacids wrapped in the contrast agent, so that it is ensured that the lipid nano-scale ultrasound contrast agent for the targeting tumor-associated macrophages can actively target the tumor-associatedmacrophages by a folic acid-folic acid receptor way; and the low-molecular-weight hyaluronic acids act on the tumor-associated macrophages, so that the tumor-associated macrophages can be transformedfrom type-M2 macrophages into type-M1 macrophages.

The invention discloses application of a paeoniflorin derivative CP-25. The application refers to application in preparation of a pharmaceutical preparation for treating human brain glioma. The structural formula of the paeoniflorin derivative CP-25 is as shown in the specification. The paeoniflorin derivative CP-25 disclsoed by the invention is capable of achieving an effect of inhibiting gliomaoccurrence and development by inhibiting tumor-associated macrophage mediated angiogenesis, and can be prepared into injection, tablets, capsules, dropping pills, granules and the like.

A cancer vaccine technology is provided which knocks out expression of cell surface immune checkpoint proteins, to facilitate their processing by immune cells, and optionally by knocking-in the expression of cytokines to boost immune response. Non-replicating tumor cells lacking cell surface CD47 are highly effective immunizing agents against subcutaneous mouse melanoma. Whole-cell vaccines inhibited tumor growth, and immunophenotyping showed a dramatic increase in activated effector cell subsets and M1-type macrophages aided by a significant reduction in the tumor-associated macrophage and myeloid derived suppressor cell compartments. A remarkable downregulation of cell surface CD47 was observed in the tumors that did escape after vaccination with genetically modified cells, suggesting the intricate involvement of CD47 in a prophylactic situation. An effective vaccination strategy to increase tumor-specific immune response in solid tumors is provided to improve the outcome of cancer immunotherapy.